19 12月 2024 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
18 12月 2024 by admin in UncategorizedComments Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
10 12月 2024 by admin in UncategorizedComments NextCure Announces Acceptance of IND Application for LNCB74
